Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons-Reference-Cited by-同舟云学术

Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons

Published:2012-02-28 Issue:3 Volume:64 Page:788-798
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Stone Rivka C.,Feng Di,Deng Jing,Singh Sukhwinder,Yang Lisong,Fitzgerald-Bocarsly Patricia,Eloranta Maija-Leena,Rönnblom Lars,Barnes Betsy J.

Funder

NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases)

Arthritis Foundation

Alliance for Lupus Research

King Gustaf V's 80-Year Foundation

Swedish Research Council

Swedish Rheumatism Association

Torsten and Ragnar Söderberg Foundation

COMBINE

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference47 articles.

1. The type I interferon system in the development of lupus;Ronnblom;Semin Immunol,2011

2. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus;Graham;Proc Natl Acad Sci U S A,2007

3. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans;Kelly;Genes Immun,2008

4. Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population;Shin;Arthritis Res Ther,2007

5. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus;Sigurdsson;Hum Mol Genet,2008

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic immune cell dysregulation and molecular subtypes revealed by single-cell RNA-seq of subjects with type 1 diabetes;Genome Medicine;2024-03-27

2. Targeting type I interferons in systemic lupus erythematous;Frontiers in Pharmacology;2023-01-16

3. The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial;Arthritis & Rheumatology;2021-11

4. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology;Pediatric Rheumatology;2021-09-25

5. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease;Nature Communications;2021-07-19